SCHEMBL1973580

SCHEMBL1973580

CCOC(=O)CN=Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
CTDSP1 Q9GZU7 1/20 0.48
SMN1; SMN2 Q16637 6/20 0.47
RAB9A P51151 6/20 0.47
NPC1 O15118 4/20 0.47
ALDH1A1 P00352 3/20 0.47
HTT P42858 1/20 0.47
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
USP2 O75604 1/20 0.46
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.42
MDM2 Q00987 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GSK3B P49841 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1973579 1.00 MEN1 (0.53) MEN1KMT2ACTDSP1SMN1; SMN2RAB9A
SCHEMBL2617527 1.00 MEN1 (0.53) MEN1KMT2ACTDSP1SMN1; SMN2RAB9A
SCHEMBL13925576 0.91 MIF (0.49) MEN1KMT2ACTDSP1SMN1; SMN2RAB9A
SCHEMBL4304419 0.86 MIF (0.45) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL11928961 0.86 MIF (0.45) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL4305863 0.86 MIF (0.45) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL13499996 0.85 PLA2G7 (0.40) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL3384931 0.84 LMNA (0.52) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL6118220 0.84 LMNA (0.52) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL687935 0.84 LMNA (0.52) MEN1KMT2ASMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117865844-A Continuous synthesis method of ethyl benzaminoacetate 新疆兴发化工有限公司 2024-04-12 CN claimed
CN-117865844-A Continuous synthesis method of ethyl benzaminoacetate 新疆兴发化工有限公司 2024-04-12 CN disclosed
US-11667631-B2 FGFR4 inhibitor, preparation method therefor, and applications thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-06-06 US disclosed
CN-113461690-B Synthesis method of chiral 4,6-dioxooctahydropyrrolo [3,4-c ] pyrrole-1-carboxylate compound 中国科学院大连化学物理研究所 2023-03-31 CN disclosed
CN-109796353-B Synthetic method of 5-aminolevulinic acid hydrochloride 福建南方制药股份有限公司 2022-04-15 CN disclosed
CN-113461690-A Synthesis method of chiral 4, 6-dioxooctahydropyrrolo [3,4-c ] pyrrole-1-carboxylic ester compound 中国科学院大连化学物理研究所 2021-10-01 CN disclosed
US-20190276451-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-09-12 US disclosed
CN-109796353-A A kind of synthetic method of 5-aminoketoglutarate hydrochloride 福建南方济民医药研发中心有限公司 2019-05-24 CN disclosed
EP-3444250-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2019-02-20 EP disclosed
EP-2586769-B1 METHOD FOR PRODUCING (1R, 2S)-1-AMINO-2-VINYL CYCLOPROPANE CARBOXYLIC ACID ESTER THAT HAS IMPROVED OPTICAL PURITY KANEKA CORP (JP) 2019-01-16 EP disclosed
US-4368157-A ANTICONVULSANTS, MUSCLE RELAXANTS, TRANQUILIZERS, SEDATIVES HOFFMANN-LA ROCHE INC. (US) 1983-01-11 US disclosed
US-4368158-A ANTICONVULSANTS, MUSCLE RELAXANTS, TRANQUILIZERS, SEDATIVES HOFFMANN-LA ROCHE INC. (US) 1983-01-11 US disclosed
EP-0068373-A1 Schiff bases of aminocycloalcanecarboxylic esters, preparation thereof and use thereof as intermediate products BASF Aktiengesellschaft (DE) 1983-01-05 EP disclosed
US-4347365-A ANTICONVULSANTS, MUSCLE RELAXANTS, SEDATIVES HOFFMANN-LA ROCHE INC. (US) 1982-08-31 US disclosed
US-4347364-A INTERMEDIATES THEREFOR HOFFMANN-LA ROCHE INC. (US) 1982-08-31 US disclosed
US-4332958-A Benzylidene glycine ester derivatives ZOECON CORPORATION (US) 1982-06-01 US disclosed
EP-0047516-A1 Propylamine derivative and process of manufacturing the same TORAY INDUSTRIES, INC. (JP) 1982-03-17 EP disclosed
US-4307237-A ANTICONVULSANTS, SEDATIVES, MUSCLE RELAXANTS HOFFMANN-LA ROCHE INC. (US) 1981-12-22 US disclosed
US-4298760-A Process for preparing 1-aminocyclopropane-1-carboxylic acid ZOECON CORPORATION (US) 1981-11-03 US disclosed
US-4280957-A Imidazodiazepines and processes therefor HOFFMANN-LA ROCHE INC. (US) 1981-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276451-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF FGFR4, FGFR1, FGFR2 MEN1 1112/4885KMT2A 2300/4885CTDSP1 2844/4885
US-11667631-B2 FGFR4 inhibitor, preparation method therefor, and applications thereof FGFR4, FGFR1, FGFR2 MEN1 1112/4885KMT2A 2300/4885CTDSP1 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.